ComeBack Mobility

Market position

A small, venture-backed medical device and digital health company in orthopedic rehabilitation and remote patient monitoring, classified as pre-seed/seed stage with roughly 12 to 50 employees. It has been recognized on the EMERGE list of the 100 most promising Central and Eastern European startups and profiled as one of Ukraine's notable medtech innovations. Companies cited as comparable include OPUM Technologies, Sensoria Health and Ceriter.

The company positions crutch-mounted sensors against in-shoe insole alternatives, arguing that crutch tips remain with the patient at all times including at night when barefoot, are more durable with a three-year service life, fit any age or shoe size, are less costly to implement and suit a reusable model. A second differentiator is the pairing of the device with patient-specific weight-bearing protocols computed from post-operative CT-based finite element analysis rather than a generic "weight-bearing as tolerated" instruction, and a reimbursement pathway that lets clinicians bill for remote therapeutic monitoring of protocol compliance.

Technology

The system combines load-sensing crutch tips with Bluetooth connectivity to a patient smartphone app and a clinician web dashboard. Load on the injured limb is computed by subtracting the weight transferred through the crutches from the patient's body weight during the phase of gait when the healthy leg is off the ground; stated accuracy is 98.5%. Thresholds can be set from 0% non-weight-bearing up to 50% partial weight-bearing, with an 80% ceiling for graduated weight-bearing as tolerated, and the device provides real-time auditory and app alerts for over- or under-loading. The tips have an IP54 dust and water rating, a stated three-year usable life, and fit canes 17–30 mm in diameter. A protocol-generation layer applies finite element analysis to post-operative CT scans to derive patient-specific loading and step targets.

Go-to-market

The company sells through orthopedic surgeons, trauma centers, rehabilitation specialists and physical therapy practices, supported by demo requests and pricing/technical-specification enquiries on its website. It builds credibility through clinical evidence and endorsements from orthopedic and physical therapy faculty, a network of clinical advisors and mentors at institutions including NYU Langone, Hospital for Special Surgery, Kaiser Permanente and UT Health San Antonio, and an in-house clinical research organization arm. Adoption is further supported by the reimbursement argument that providers can bill for remote therapeutic monitoring of protocol compliance.

Orthopedic surgeons, trauma and rehabilitation departments, hospitals, physical therapy clinics and their patients recovering from surgical and nonsurgical treatment of hip, thigh, knee, shin, ankle and foot injuries who must follow controlled partial weight-bearing protocols. Payers are cited as indirect beneficiaries through avoided revision surgeries and disability costs.

Geography

Dual US–Ukraine operations. The US entity, ComeBack Mobility INC, lists an office at 700 N St Mary's Street, San Antonio, Texas; other listings associate the company with Queens and New York, NY, and Jackson, Wyoming. Contract manufacturing is handled by FISON LLC in Dnipro, Ukraine, and a clinical research organization entity, ComeBack Mobility LLC, is based in Kyiv. Most devices are assembled in Ukraine apart from some components sourced from China. Clinical trials have been conducted in Ukraine, Germany and the US, and the founder has said products were launched into 36 countries.

History

Founded in 2020 as a Ukrainian-American venture, the company was among 14 startups included in the EMERGE list of the 100 most promising startups in Central and Eastern Europe. In 2021 it announced a combined $1 million in pre-seed and seed financing from Fison, Peter Chernyshov, Farmak, the Ukrainian diaspora in Chicago and angel investors from Ukraine, Belgium and the US. Founder Ilya Popov publicly described operating a half-Ukrainian startup through the war, and the company continued clinical and commercial work across Ukraine, Germany and the US. An independent validation study of the crutch tip biofeedback device was published in January 2024. The company participated in the Techstars network and maintains offices in San Antonio, Texas, with contract manufacturing and clinical research entities in Dnipro and Kyiv, Ukraine.

Risks & controversies

The company's manufacturing and clinical research operations are located in Ukraine and have been exposed to the disruption of the war, a topic the founder has written about publicly. The device itself is not separately reimbursed by insurers because it is a new technology, with coverage limited to associated physician services, which may constrain adoption. The device is FDA registered as a Class II, 510(k)-exempt product rather than FDA approved; the company's own homepage separately refers to it as FDA cleared, while its patient FAQ states it does not require FDA approval. Public funding data is inconsistent across third-party listings, and the company is at an early commercial stage with a small team.